Anti-PTRF/Cavin-1 Antibody (C15-1317-002)

General description

Polymerase I and transcript release factor (UniProt Q6NZI2; also known as Cavin-1, PTRF, RNA polymerase I and transcript release factor, TTF-I interacting peptide 12) is encoded by the PTRF (also known as CGL4, CAVIN, CAVIN1, FKSG13) gene (Gene ID 284119) in human. Cavin-1 is the founding member of the PTRF/Cavin family of cytoplasmic proteins whose expressions are essential for caveola formation. PTRF/Cavin-1, serum deprivation response (SDR)/Cavin-2, SDR-related gene product that binds to C kinase (SRBC)/Cavin-3, and muscle-restricted coiled-coil protein (MURC)/Cavin-4, form an oligomeric assembly termed Cavin complex in the cytosol and associate with caveolin at plasma membrane caveolae. Research shows an essential role for PTRF/Cavin-1 but not the other family members in caveola formation and recruitment of the cavin complex to the plasma membrane. In prostate cancer PC3 cells and during development of zebrafish notochord, lack of PTRF-Cavin expression correlates with lack of caveolae, where caveolin displays increased lateral mobility on the plasma membrane and accelerated lysosomal degradation. Expression of Cavin-1 restores caveolae formation in PC3 cells. Likewise the absence of cavin-1 is also observed in advanced prostate carcinoma. PTRF gene mutations are known to cause congenital generalized lipodystrophy 4 (CGL4).

Specificity

Expected to react with spliced isoforms 1 and 2, but not isoform 3.

Immunogen

Linear peptide corresponding to the N-terminus of human PTRF/Cavin-1.

Application

Anti-PTRF/Cavin-1 Antibody is an antibody against PTRF/Cavin-1 for use in Western Blotting, Immunohistochemistry (Paraffin), Immunocytochemistry.

Western Blotting Analysis: A representative lot detected PTRF/Cavin-1 expression in HeLa, but not in prostate cancer cell lines, LNCaP, 22Rv1 and PC-3 (Moon, H., et al. (2014). Oncogene 33(27):3561-3570).
Western Blotting Analysis: A representative lot detected exogenously expressed human PTRF/Cavin-1 in transfected 22Rv1 and LNCaP cells (Moon, H., et al. (2014). Oncogene 33(27):3561-3570).
Immunohistochemistry Analysis: A representative lot detected reduced PTRF/Cavin-1 immunoreactivity in paraffin-embedded malignant prostate stroma tissue samples when compared with normal prostate stroma and benign prostatic hyperplasia (BPH) specimens. A lack of PTRF/cavin-1 immunoreactivity in prostate epithelia was seen among both normal and malignant samples (Moon, H., et al. (2014). Oncogene 33(27):3561-3570).
Immunocytochemistry Analysis: A representative lot detected surface caveola localization of exogenously expressed human PTRF/Cavin-1 among transfected LNCaP cells (Moon, H., et al. (2014). Oncogene 33(27):3561-3570).

Quality

Evaluated by Western Blotting in rat skeletal muscle myoblast L6 cell lysate.

Western Blotting Analysis: A 1:1,000 dilution of this antibody detected PTRF/Cavin-1 in 10 µg of rat skeletal muscle myoblast L6 cell lysate.

Target description

~52 kDa observed.

Other Notes

Concentration: Please refer to lot specific datasheet.

biological source: rabbit. Quality Level: 100. antibody form: affinity isolated antibody. antibody product type: primary antibodies. clone: polyclonal. purified by: affinity chromatography. species reactivity: rat, human. technique(s): immunocytochemistry: suitable, immunohistochemistry: suitable (paraffin), western blot: suitable. NCBI accession no.: NP_036364. UniProt accession no.: Q6NZI2. shipped in: wet ice. target post-translational modification: unmodified. Gene Information: human ... CAVIN1(284119). Storage Class Code: 12 - Non Combustible Liquids. WGK: WGK 1. Flash Point(F): Not applicable. Flash Point(C): Not applicable.